Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in Advanced Upper GI Carcinomas
NCT00350753Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, bevacizumab in cholangiocarcinoma (CCA), gallbladder cancer, sponsored by Rigshospitalet. Started Jun 2006; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT00350753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350753.